XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy

NCT05695898 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Sponsor decision

Conditions

Metastatic Melanoma
Advanced Melanoma

Interventions

DRUG: XmAb22841
DRUG: XmAb23104

Sponsor

University of California, San Francisco

Collaborators

[object Object]